Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene

Annals of Surgical Oncology

Volumn 17, Issue 3, 2010, Pages 889-897

  Takahashi, Tsuyoshi ^a   Sonobe, Makoto ^a   Kobayashi, Masashi ^a   Yoshizawa, Akihiko ^a   Menju, Toshi ^a   Nakayama, Ei ^a   Mino, Nobuya ^a   Iwakiri, Shotaro ^a   Sato, Kiyoshi ^a   Miyahara, Ryo ^a   Okubo, Kenichi ^a   Manabe, Toshiaki ^a   Date, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CANCER PATIENT; CANCER SURGERY; CLINICAL FEATURE; FEMALE; FUSION GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HOSPITAL; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; SMOKING;

ADENOCARCINOMA; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77149130499     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0808-7     Document Type: Article

References (46)

1. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 1497 1500 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D 15118125 (Pubitemid 38720929)
2. DH Lee JY Han SY Yu, et al. 2006 The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study J Thorac Oncol 1 9 965 971 10.1097/01243894-200611000-00008 17409980
3. K Tamura I Okamoto T Kashii, et al. 2008 Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) Br J Cancer 98 5 907 914 10.1038/sj.bjc.6604249 1:CAS:528:DC%2BD1cXivVOgtbo%3D 18283321 (Pubitemid 351341609)
4. BM Qin X Chen JD Zhu DQ Pei 2005 Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy Cell Res 15 3 212 217 10.1038/sj.cr.7290289 1:CAS:528: DC%2BD2MXksFynsr8%3D 15780185 (Pubitemid 41653946)
5. W Pao V Miller M Zakowski, et al. 2004 EGF receptor mutations are common in lung cancers from "never-smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 36 13306 13311 10.1073/pnas.0405220101 1:CAS:528:DC%2BD2cXnvFems70%3D 15329413 (Pubitemid 39209661)
6. T Fukui T Mitsudomi 2008 Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers Gen Thorac Cardiovasc Surg 56 3 97 103 10.1007/s11748-007-0193-8 18340507
7. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 1497 1500 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D 15118125 (Pubitemid 38720929)
8. T Mitudomi Y Yatabe 2007 Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 12 1817 1824 10.1111/j.1349-7006.2007.00607.x (Pubitemid 350002184)
9. A Marchetti C Martella L Felicioni, et al. 2005 EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 4 857 865 10.1200/JCO.2005.08.043 1:CAS:528:DC%2BD2MXitVKit7o%3D 15681531 (Pubitemid 46224186)
10. SF Huang HP Liu LH Li, et al. 2004 High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan Clin Cancer Res 10 24 8195 8203 10.1158/1078-0432.CCR-04-1245 1:CAS:528:DC%2BD2cXhtFGjsrjK 15623594 (Pubitemid 40053378)
11. M Taron Y Ichinose R Rosell, et al. 2005 Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas Clin Cancer Res 11 16 5876 5885 10.1158/1078-0432.CCR-04-2618 (Pubitemid 41170316)
12. XL Mu LY Li XT Zhang, et al. 2005 Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer Clin Cancer Res 11 12 4289 4294 10.1158/1078-0432. CCR-04-2506 1:CAS:528:DC%2BD2MXltFelurY%3D 15958609 (Pubitemid 40825615)
13. DH Lee JY Han SY Yu, et al. 2006 The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study J Thorac Oncol 1 9 965 971 10.1097/01243894-200611000-00008 17409980
14. YL Wu WZ Zhong LY Li, et al. 2007 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland of China J Thorac Oncol 2 5 430 439 10.1097/01.JTO.0000268677.87496.4c 17473659 (Pubitemid 47181698)
15. CH Chang KY Chen Y Young-Xu, et al. 2008 The safety and efficiency of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis Lung Cancer 62 2 242 252 10.1016/j.lungcan.2008.03.001 18423782
16. A Haringhuizen H van Tinteren HF Vaessen P Bass N van Zandwijk 2004 Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients Ann Oncol 15 5 786 792 10.1093/annonc/mdh177 1:STN:280:DC%2BD2c3htFymug%3D%3D 15111348 (Pubitemid 38714741)
17. BJ Byrne J Garst 2005 Epidermal growth factor receptor inhibitions and their role in non-small-cell lung cancer Curr Oncol Rep 7 4 241 247 10.1007/s11912-005-0045-6 1:CAS:528:DC%2BD28XktVaktQ%3D%3D 15946581
18. K Tamura M Fukuoka 2005 Gefitinib in non-small cell lung cancer Expert Opin Pharmacother 6 6 985 993 10.1517/14656566.6.6.985 1:CAS:528: DC%2BD2MXltFekt70%3D 15952926 (Pubitemid 40946159)
19. K Park K Goto 2006 A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer Curr Med Res Opin 22 3 561 573 10.1185/030079906X89847 1:CAS:528:DC%2BD28XjvV2htLo%3D 16574039
20. WC Lin CH Chiu JL Liou YM Chen RP Perng CM Tsai 2006 Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer Lung Cancer 54 2 193 199 10.1016/j.lungcan.2006.07.013 16996166 (Pubitemid 44764919)
21. AS Tsao XM Tang B Sabloff, et al. 2006 Clinicopathologic characteristics of the EGFR mutations in non-small cell lung cancer J Thorac Oncol 1 3 231 239 17409862 (Pubitemid 47181440)
22. T Kosaka Y Yatabe H Endoh H Kuwano T Takahashi T Mitsudomi 2004 Mutations of the epidermal growth factor gene in lung cancer: biological and clinical implications Cancer Res 64 24 8919 8923 10.1158/0008-5472.CAN-04-2818 1:CAS:528:DC%2BD2cXhtVOmsL3P 15604253 (Pubitemid 39665498)
23. T Mitsudomi T Kosaka H Endoh, et al. 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 11 2513 2520 10.1200/JCO.2005.00.992 1:CAS:528: DC%2BD2MXjvVyktLs%3D 15738541 (Pubitemid 47050841)
24. M Soda YL Choi M Enomoto, et al. 2007 Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 7153 561 566 10.1038/nature05945 1:CAS:528:DC%2BD2sXosVSrtrs%3D 17625570 (Pubitemid 47206930)
25. YL Choi K Takeuchi M Soda, et al. 2008 Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer Cancer Res 68 13 4971 4976 10.1158/0008-5472.CAN-07-6158 1:CAS:528:DC%2BD1cXnvFOqsbY%3D 18593892
26. JP Koivunen C Mermel K Zejnullahu, et al. 2008 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 13 4275 4283 10.1158/1078-0432.CCR-08-0168 1:CAS:528:DC%2BD1cXnvFyks7s%3D 18594010
27. K Takeuchi YL Choi M Soda, et al. 2008 Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts Clin Cancer Res 14 20 6618 6624 10.1158/1078-0432.CCR-08-1018 1:CAS:528:DC%2BD1cXht1Kgur7L 18927303
28. M Sonobe T Manabe H Wada F Tanaka 2005 Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma Br J Cancer 93 3 355 363 10.1038/sj.bjc.6602707 1:CAS:528:DC%2BD2MXmvFensLY%3D 16052218 (Pubitemid 43080038)
29. M Sonobe T Manabe H Wada F Tanaka 2006 Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain JMD. 8 351 356 1:CAS:528: DC%2BD28XnsFGnsb0%3D 16825508
30. Y Fukuyoshi H Inoue Y Kita, et al. 2008 EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers Br J Cancer 98 9 1536 1539 10.1038/sj.bjc.6604341 1:CAS:528:DC%2BD1cXltl2itL4%3D 18414414 (Pubitemid 351652334)
31. S Perner PL Wagner F Demichelis, et al. 2008 EML4-ALK fusion lung cancer: a rare acquired event Neoplasia 10 3 298 302 1:CAS:528:DC%2BD1cXltleitL4%3D 18320074
32. K Shinmura S Kageyama H Tao, et al. 2008 EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas Lung Cancer 61 2 163 169 10.1016/j.lungcan.2007.12.013 18242762
33. K Inamura K Takeuchi Y Togashi, et al. 2008 EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J Thorac Oncol 3 1 13 17 10.1097/JTO.0b013e31815e8b60 18166835
34. K Inamura K Takeuchi Y Togashi, et al. 2009 EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset Mod Pathol 22 4 508 515 10.1038/modpathol.2009.2 1:CAS:528:DC%2BD1MXjslyqtLc%3D 19234440
35. MP Martelli G Sozzi L Hernandez, et al. 2009 EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues Am J Pathol 174 2 661 670 10.2353/ajpath.2009.080755 1:CAS:528:DC%2BD1MXivVWntLo%3D 19147828
36. DW Wong EL Leung KK So, et al. 2009 The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 115 8 1723 1733 10.1002/cncr.24181 1:CAS:528: DC%2BD1MXltVOnur4%3D 19170230
37. M Soda S Takada K Takeuchi, et al. 2008 A mouse model for EML4-ALK-positive lung cancer Proc Natl Acad Sci U S A 105 50 19893 19897 10.1073/pnas.0805381105 1:CAS:528:DC%2BD1cXhsFCmtb7F 19064915
38. H Sasaki S Shimizu K Endo, et al. 2006 EGFR and erbB2 mutation status in Japanese lung cancer patients Int J Cancer 118 1 180 184 10.1002/ijc.21301 1:CAS:528:DC%2BD2MXht1KgsrrE 16003726 (Pubitemid 41681596)
39. T Takano T Fukui Y Ohe, et al. 2008 EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan J Clin Oncol 26 34 5589 5595 10.1200/JCO.2008.16.7254 1:CAS:528:DC%2BD1MXmsVSkug%3D%3D 18794545
40. P Stephens C Hunter G Bignell, et al. 2004 Lung cancer: intragenic ERBB2 kinase mutations in tumors Nature 431 7008 525 526 10.1038/431525b 1:CAS:528:DC%2BD2cXnvFCntLg%3D 15457249
41. H Shigematsu T Takahashi M Nomura, et al. 2005 Somatic mutations of the HER2 kinase domain in lung adenocarcinomas Cancer Res 65 1 1642 1646 10.1158/0008-5472.CAN-04-4235 1:CAS:528:DC%2BD2MXitVOjs7o%3D 15753357 (Pubitemid 40478587)
42. H Sasaki S Shimizu K Endo, et al. 2006 EGFR and erbB2 mutations status in Japanese lung cancer Int J Cancer 118 1 180 184 10.1002/ijc.21301 1:CAS:528:DC%2BD2MXht1KgsrrE 16003726 (Pubitemid 41681596)
43. N Noda D Matsuzoe T Konno K Kawahara Y Yamashita T Shirakusa 2001 K-ras gene mutations in non-small cell lung cancer in Japanese Oncol Rep 8 4 889 892 1:CAS:528:DC%2BD3MXlt1egsbg%3D 11410804
44. T Shibata S Hanada A Kokubo, et al. 2007 Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma Cancer Sci 98 7 985 991 10.1111/j.1349-7006.2007.00483.x 1:CAS:528: DC%2BD2sXnsVOqsr4%3D 17459062 (Pubitemid 46865381)
45. M Sonobe M Nakagawa K Takenaka, et al. 2007 Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer J Surg Oncol. 95 63 69 10.1002/jso.20547 1:CAS:528:DC%2BD2sXhs12hs7s%3D 17192868 (Pubitemid 46122720)
46. K Takeuchi YL Choi Y Togashi, et al. 2009 KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer Clin Cancer Res 15 9 3143 3149 10.1158/1078-0432.CCR- 08-3248 1:CAS:528:DC%2BD1MXltFOrtbY%3D 19383809